Very cool! Watching
$Tenaya Therapeutics(TNYA.US$ Tenaya Therapeutics Publishes TN-401 Gene Therapy Preclinical Data In Nature Communications Medicine
Moomoo 24/7· 9 mins ago
TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
PKP2 Gene Replacement Therapy Normalized Heart Rhythms, Reversed Disease Progression and Extended Survival in a Severe Mouse Model of Disease
Tenaya Anticipates Dosing First Patient in Phase 1b RIDGE-1 Clinical Trial of TN-401
in Second Half of 2024
Moomoo 24/7· 9 mins ago
TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
PKP2 Gene Replacement Therapy Normalized Heart Rhythms, Reversed Disease Progression and Extended Survival in a Severe Mouse Model of Disease
Tenaya Anticipates Dosing First Patient in Phase 1b RIDGE-1 Clinical Trial of TN-401
in Second Half of 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
